I used to own INO and sold 100% of it after reading a letter from one of the directors who quit about a couple years ago. INO is more speculative for serveral reasons in my opinion, and would say another stem cell company is a better play. I would diversify with ATHX. Both NBS and ATHX have a strong stem cell platform (a different portfolio of treatments), and both will have a major catalyst before the end of the year, which could drive the price higher. I suspect NBS can go 5X-10X higher before the end of the year. But I believe ATHX can go 25X higher before the end of the year with its positive catalyst. The down side is the risk of ATHX failing and the stock price going down 80%+ whereas NBS failing would only fall around 35% (discounting the fact that NBS has significant sales 1Xratio from services unlike ATHX which can only reley on a successful clinical trial).
After some consideration, I decided to hold, and prob add. This is too good of a segment to sell, esp. when this stock is going sideways. It will soon go up. I did also jump into ONCS, also think it has bottomed.